[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Zhao et al., 2016 - Google Patents

Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes

Zhao et al., 2016

View HTML
Document ID
14195351956352529096
Author
Zhao H
Heimberger A
Lu Z
Wu X
Hodges T
Song R
Shen J
Publication year
Publication venue
Oncotarget

External Links

Snippet

Background Tumor-based molecular biomarkers have redefined in the classification gliomas. However, the association of systemic metabolomics with glioma phenotype has not been explored yet. Methods In this study, we conducted two-step (discovery and validation) …
Continue reading at pmc.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer

Similar Documents

Publication Publication Date Title
Zhao et al. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes
Oh et al. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
Ippolito et al. Sexual dimorphism in glioma glycolysis underlies sex differences in survival
Ricci et al. Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
Terunuma et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis
Huang et al. A prospective study of serum metabolites and glioma risk
Wang et al. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients
An et al. Integrative analysis of plasma metabolomics and proteomics reveals the metabolic landscape of breast cancer
Xing et al. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma
Jiang et al. Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma
Li et al. Cuproptosis identifies respiratory subtype of renal cancer that confers favorable prognosis
Yehia et al. Distinct alterations in tricarboxylic acid cycle metabolites associate with cancer and autism phenotypes in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome
Miralaei et al. Integrated pan‐cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance
Euceda et al. Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
Trautwein et al. Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment
Xu et al. Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry
Meier et al. Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
Yuan et al. NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer
Zhao et al. Essential amino acids deprivation is a potential strategy for breast cancer treatment
Mao et al. Bioinformatics Identification of Ferroptosis‐Associated Biomarkers and Therapeutic Compounds in Psoriasis
Guo et al. In vitro and in vivo analysis of metabolites involved in the TCA cycle and glutamine metabolism associated with cisplatin resistance in human lung cancer
Ding et al. Novel serum peptide model revealed by MALDI-TOF-MS and its diagnostic value in early bladder cancer
Ucal et al. Proteomic analysis reveals differential protein expression in variants of papillary thyroid carcinoma
Sharma et al. Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes
Wu et al. Exploring the relationship between metabolism and immune microenvironment in osteosarcoma based on metabolic pathways